NOTCH1 and neoplasm: Other lines of evidence indicate that ESA+/CD44+/CD24low breast CSCs showed high levels of Notch1 and Notch4, although Notch4 blockade was more effective in inhibiting tumor initiation in vivo (Harrison et al., 2010a,b).